In short
Clinical trials are underway to assess the safety, tolerability, and immunogenicity of V116, a new 21-valent pneumococcal conjugate vaccine. These studies aim to evaluate V116 in different age groups and populations at increased risk for pneumococcal disease. The trials compare V116 to existing pneumococcal vaccines and measure immune responses and adverse events following vaccination.
At a glance
- Vaccine
- V116 (21-valent pneumococcal conjugate vaccine)
- Study Populations
- Adults 18-64 at increased risk, adults 50+, children/adolescents with risk factors
- Comparator
- PPSV23 (23-valent pneumococcal polysaccharide vaccine)
- Primary Outcomes
- Safety (adverse events), Immunogenicity (OPA and IgG levels)
- Secondary Outcomes
- Geometric mean fold rise, proportion with 4-fold antibody increase
- Risk Conditions
- Diabetes, liver disease, lung disease, heart disease, kidney disease
- Administration
- Intramuscular injection, 0.5 mL dose
- Follow-up Period
- Primary measurements at 30 days post-vaccination
What is V116?
V116 is a new pneumococcal vaccine being developed to protect against pneumococcal disease. Pneumococcal disease is an infection caused by bacteria called Streptococcus pneumoniae, also known as pneumococcus. These bacteria can cause various illnesses, ranging from mild to severe, including pneumonia, ear infections, sinus infections, and more serious invasive diseases like meningitis and bloodstream infections.
This vaccine is known as a 21-valent conjugate vaccine, which means it targets 21 different types (serotypes) of pneumococcal bacteria. The term "conjugate" refers to the way the vaccine is made, linking (or conjugating) parts of the bacteria to a carrier protein to enhance the immune response.
Who is V116 for?
V116 is being developed for several groups of people who are at increased risk of pneumococcal disease:
- Adults aged 18 to 64 years with certain medical conditions that increase their risk of pneumococcal disease
- Adults aged 50 years and older
- Children and adolescents with increased risk of pneumococcal disease
The medical conditions that may increase the risk of pneumococcal disease include:
- Diabetes mellitus (treated with medication)
- Chronic liver disease
- Chronic lung diseases like COPD (Chronic Obstructive Pulmonary Disease) or asthma
- Chronic heart disease
- Chronic kidney disease
How V116 Works
V116 works by stimulating the body's immune system to produce antibodies against 21 different types of pneumococcal bacteria. These antibodies help the body recognize and fight off these bacteria if you're exposed to them in the future.
The vaccine contains small parts of the pneumococcal bacteria, called polysaccharides, which are linked (conjugated) to a carrier protein called CRM197. This conjugation helps to create a stronger and longer-lasting immune response, especially in young children.
Clinical Trials
V116 is currently being studied in several Phase 3 clinical trials. These are large-scale studies designed to confirm the safety and effectiveness of the vaccine before it can be approved for general use. The trials are focusing on different groups:
- Adults aged 18 to 64 years with increased risk of pneumococcal disease
- Adults aged 50 years and older
- Children and adolescents with increased risk of pneumococcal disease
In these trials, researchers are looking at how well V116 stimulates the immune system to produce antibodies against pneumococcal bacteria. They're measuring this by looking at the levels of antibodies in the blood and how well these antibodies can kill pneumococcal bacteria in laboratory tests.
Safety and Side Effects
A key part of these clinical trials is to assess the safety of V116. Researchers are carefully monitoring for any side effects or adverse events that occur after vaccination. Some of the things they're specifically looking at include:
- Injection site reactions (like pain, redness, or swelling where the vaccine was given)
- Systemic reactions (like fever, fatigue, or headache)
- Any serious adverse events that might be related to the vaccine
It's important to note that while these potential side effects are being studied, they are common with many vaccines and usually mild and short-lived. The benefits of protection against pneumococcal disease typically far outweigh the risks of vaccination.
Conclusion
V116 is a promising new pneumococcal vaccine that could offer protection against a wide range of pneumococcal bacteria. It's being developed for both adults and children who are at increased risk of pneumococcal disease. While it's still in the clinical trial phase, the results of these studies will help determine if V116 is safe and effective for use in the general population. If successful, it could become an important tool in preventing pneumococcal disease and its complications.